Current and Future Therapies for Myasthenia Gravis

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 1997 Aug 1

PMID 9259176

Authors

Q Yi

A K Lefvert

Affiliations

Soon will be listed here.

Abstract

Myasthenia gravis (MG) is undoubtedly the most thoroughly understood of all human autoimmune diseases. The basic defect in the disease is a decrease in the number of available acetylcholine receptors (AChR) at neuromuscular junctions caused by an antibody-mediated autoimmune attack. Current treatments aimed at restoring the available AChR, depleting the autoantibodies or suppressing the immune system have been so effective that most patients can lead normal lives. However, prolonged drug treatment is required, and this carries a potential risk of drug toxicity and, in the case of immunosuppressants, systemic immunosuppression. The ideal treatment for MG would eliminate only the abnormal autoimmune response without interfering with the immune system. During the past 20 years, impressive advances have been made in our understanding of the immunology and molecular biology of MG. Accordingly, it should be possible to design rational and immune-based therapies in the future. In this article, we briefly review the current treatment modalities for MG, and discuss the prospects for immunotherapy.

References

Shenoy M, Baron S, Wu B, Goluszko E, Christadoss P . IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis. J Immunol. 1995; 154(11):6203-8. View

Trentham D, Orav E, Combitchi D, Lorenzo C, Sewell K, Hafler D . Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993; 261(5129):1727-30. DOI: 10.1126/science.8378772. View

Sommer N, Willcox N, Harcourt G, Newsom-Davis J . Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol. 1990; 28(3):312-9. DOI: 10.1002/ana.410280303. View

Finck B, Linsley P, Wofsy D . Treatment of murine lupus with CTLA4Ig. Science. 1994; 265(5176):1225-7. DOI: 10.1126/science.7520604. View

Papatestas A, GENKINS G, KORNFELD P, Eisenkraft J, Fagerstrom R, Pozner J . Effects of thymectomy in myasthenia gravis. Ann Surg. 1987; 206(1):79-88. PMC: 1492935. DOI: 10.1097/00000658-198707000-00013. View

Wekerle H, Ketelsen U . Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet. 1977; 1(8013):678-80. DOI: 10.1016/s0140-6736(77)92118-3. View

Swain S, Dialynas D, Fitch F, English M . Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. J Immunol. 1984; 132(3):1118-23. View

Bach J . Immunosuppressive therapy of autoimmune diseases. Immunol Today. 1993; 14(6):322-6. DOI: 10.1016/0167-5699(93)90053-N. View

Zisman E, Dayan M, Kirshner S, Karni A, Abramsky O, Brautbar C . Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis. Proc Natl Acad Sci U S A. 1996; 93(9):4492-7. PMC: 39566. DOI: 10.1073/pnas.93.9.4492. View

10.

Gajdos P, Outin H, Elkharrat D, Brunel D, Raphael J, GOULON M . High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984; 1(8373):406-7. DOI: 10.1016/s0140-6736(84)90469-0. View

11.

Killen J, Hochschwender S, Lindstrom J . The main immunogenic region of acetylcholine receptors does not provoke the formation of antibodies of a predominant idiotype. J Neuroimmunol. 1985; 9(3-4):229-41. DOI: 10.1016/s0165-5728(85)80021-7. View

12.

Tindall R, Phillips J, Rollins J, Wells L, Hall K . A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993; 681:539-51. DOI: 10.1111/j.1749-6632.1993.tb22937.x. View

13.

Ahlberg R, Yi Q, Pirskanen R, Matell G, Sundevall A, ABERG B . The effect of thymectomy on autoreactive T- and B-lymphocytes in myasthenia gravis. J Neuroimmunol. 1997; 74(1-2):45-54. DOI: 10.1016/s0165-5728(96)00204-4. View

14.

Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S . Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994; 57(5):578-81. PMC: 1072918. DOI: 10.1136/jnnp.57.5.578. View

15.

Reim J, McIntosh K, Martin S, Drachman D . Specific immunotherapeutic strategy for myasthenia gravis: targeted antigen-presenting cells. J Neuroimmunol. 1992; 41(1):61-70. DOI: 10.1016/0165-5728(92)90196-r. View

16.

Mowat A . The regulation of immune responses to dietary protein antigens. Immunol Today. 2014; 8(3):93-8. DOI: 10.1016/0167-5699(87)90853-X. View

17.

Fonseca V, Havard C . Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J. 1990; 66(772):102-5. PMC: 2429542. DOI: 10.1136/pgmj.66.772.102. View

18.

Ahlberg R, Yi Q, Eng H, Pirskanen R, Lefvert A . T-cell epitopes on the human acetylcholine receptor alpha-subunit residues 10-84 in myasthenia gravis. Scand J Immunol. 1992; 36(3):435-42. DOI: 10.1111/j.1365-3083.1992.tb02958.x. View

19.

Kirshner S, Sela M, Mozes E . Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Proc Natl Acad Sci U S A. 1993; 90(15):7000-4. PMC: 47063. DOI: 10.1073/pnas.90.15.7000. View

20.

Perez M, Buot W, Bagabaldo Z, Renales L . Stable remissions in myasthenia gravis. Neurology. 1981; 31(1):32-7. DOI: 10.1212/wnl.31.1.32. View